Last reviewed · How we verify
Vaginal conjugated estrogens
At a glance
| Generic name | Vaginal conjugated estrogens |
|---|---|
| Also known as | Premarin Vaginal Cream |
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery (PHASE3)
- Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity (PHASE4)
- Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (PHASE4)
- Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse (NA)
- Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy (PHASE4)
- Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection (NA)
- Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen (PHASE4)
- Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaginal conjugated estrogens CI brief — competitive landscape report
- Vaginal conjugated estrogens updates RSS · CI watch RSS
- Emory University portfolio CI